I 
119TH CONGRESS 
1ST SESSION H. R. 1476 
To amend title XVIII of the Social Security Act to provide a phase-in 
for plasma-derived products under the manufacturer discount program. 
IN THE HOUSE OF REPRESENTATIVES 
FEBRUARY 21, 2025 
Mr. HUDSON (for himself, Mr. DAVIS of North Carolina, Mr. MURPHY, and 
Mr. PETERS) introduced the following bill; which was referred to the 
Committee on Energy and Commerce, and in addition to the Committee 
on Ways and Means, for a period to be subsequently determined by the 
Speaker, in each case for consideration of such provisions as fall within 
the jurisdiction of the committee concerned 
A BILL 
To amend title XVIII of the Social Security Act to provide 
a phase-in for plasma-derived products under the manu-
facturer discount program. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Preserving Life-saving 
Access to Specialty Medicines in America Act’’ or the 
‘‘PLASMA Act’’. 
VerDate Sep 11 2014 
21:34 Mar 12, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1476.IH
H1476
ssavage on LAPJG3WLY3PROD with BILLS
SEC. 2. PHASE-IN FOR PLASMA-DERIVED PRODUCTS UNDER 
MANUFACTURER DISCOUNT PROGRAM. 
Section 1860D–14C(g)(4) of the Social Security Act 
(42 U.S.C. 1395w–114c(g)(4)) is amended— 
(1) in subparagraph (A), in the matter pre-
ceding clause (i), by striking ‘‘and (C)’’ and insert-
ing ‘‘, (C), and (D)’’; 
(2) by redesignating subparagraphs (D) and 
(E) as subparagraphs (E) and (F), respectively; and 
(3) by inserting after subparagraph (C) the fol-
lowing: 
‘‘(D) PHASE-IN
FOR
PLASMA-DERIVED 
PRODUCTS.— 
‘‘(i) IN
GENERAL.—For 2026 and 
subsequent years, subject to clause (iv), in 
the case of an applicable drug of a manu-
facturer that is a plasma-derived product 
(as defined in clause (ii)), and that is mar-
keted as of August 16, 2022, and dis-
pensed for an applicable beneficiary, the 
term ‘discounted price’ means the specified 
plasma-derived product percent (as defined 
in clause (iii)) of the negotiated price of 
the applicable drug of the manufacturer. 
‘‘(ii) PLASMA-DERIVED PRODUCT.—In 
this subparagraph, the term ‘plasma-de-
VerDate Sep 11 2014 
21:34 Mar 12, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1476.IH
H1476
ssavage on LAPJG3WLY3PROD with BILLS
rived product’ means an applicable drug 
that is a biological product that is derived 
from human whole blood or plasma. 
‘‘(iii) 
SPECIFIED
PLASMA-DERIVED 
PRODUCT
PERCENT.—In this subpara-
graph, the term ‘specified plasma-derived 
product percent’ means, with respect to a 
year— 
‘‘(I) for an applicable drug that 
is a plasma-derived product dispensed 
for an applicable beneficiary who has 
not incurred costs, as determined in 
accordance 
with 
section 
1860D– 
2(b)(4)(C), for covered part D drugs 
in the year that are equal to or exceed 
the annual out-of-pocket threshold 
specified 
in 
section 
1860D– 
2(b)(4)(B)(i) for the year— 
‘‘(aa) for 2026, 99 percent; 
‘‘(bb) for 2027, 98 percent; 
‘‘(cc) for 2028, 95 percent; 
‘‘(dd) for 2029, 92 percent; 
and 
‘‘(ee) for 2030 and each 
subsequent year, 90 percent; and 
VerDate Sep 11 2014 
21:34 Mar 12, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1476.IH
H1476
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(II) for an applicable drug that 
is a plasma-derived product dispensed 
for an applicable beneficiary who has 
incurred costs, as determined in ac-
cordance 
with 
section 
1860D– 
2(b)(4)(C), for covered part D drugs 
in the year that are equal to or exceed 
the annual out-of-pocket threshold 
specified 
in 
section 
1860D– 
2(b)(4)(B)(i) for the year— 
‘‘(aa) for 2026, 99 percent; 
‘‘(bb) for 2027, 98 percent; 
‘‘(cc) for 2028, 95 percent; 
‘‘(dd) for 2029, 92 percent; 
‘‘(ee) for 2030, 90 percent; 
‘‘(ff) for 2031, 85 percent; 
and 
‘‘(gg) for 2032 and each 
subsequent year, 80 percent. 
‘‘(iv) LIMITATIONS.—This subpara-
graph shall not apply with respect to the 
following: 
‘‘(I) CERTAIN DRUGS DISPENSED 
TO LIS BENEFICIARIES.—An applica-
VerDate Sep 11 2014 
21:34 Mar 12, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H1476.IH
H1476
ssavage on LAPJG3WLY3PROD with BILLS
ble drug described in subparagraph 
(B)(i). 
‘‘(II) SPECIFIED
SMALL
MANU-
FACTURERS.—An applicable drug de-
scribed in subparagraph (C)(i).’’. 
Æ 
VerDate Sep 11 2014 
21:34 Mar 12, 2025
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H1476.IH
H1476
ssavage on LAPJG3WLY3PROD with BILLS